Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
8.66
+0.11 (1.29%)
Aug 10, 2026, 10:07 AM EDT - Market open
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $74.27M in the quarter ending June 30, 2026, with 88.02% growth. This brings the company's revenue in the last twelve months to $239.66M, up 110.16% year-over-year. In the year 2025, Phathom Pharmaceuticals had annual revenue of $175.11M with 216.93% growth.
Revenue (ttm)
$239.66M
Revenue Growth
+110.16%
P/S Ratio
2.83
Revenue / Employee
$645,989
Employees
371
Market Cap
687.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 175.11M | 119.86M | 216.93% |
| Dec 31, 2024 | 55.25M | 54.57M | 8,001.47% |
| Dec 31, 2023 | 682.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 355.17M |
| REGENXBIO | 174.48M |
| Zevra Therapeutics | 136.07M |
| Crescent Biopharma | 11.88M |
| Neurogene | 925.00K |
| Allogene Therapeutics | 22.00K |
PHAT News
- 10 days ago - Phathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum - TheFly
- 10 days ago - Phathom Pharmaceuticals price target lowered to $21 from $28 at Raymond James - TheFly
- 10 days ago - Phathom Pharmaceuticals price target lowered to $22 from $25 at Guggenheim - TheFly
- 10 days ago - Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham - TheFly
- 11 days ago - Phathom Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 11 days ago - Phathom Pharmaceuticals Earnings release: Q2 2026 - Filings
- 11 days ago - Phathom Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 11 days ago - Phathom Pharmaceuticals Slides: Q2 2026 - Filings